3.86
price down icon2.81%   -0.1117
after-market 시간 외 거래: 3.86
loading
전일 마감가:
$3.9717
열려 있는:
$4.0797
하루 거래량:
9,169
Relative Volume:
0.42
시가총액:
$21.57M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.698
EPS:
-5.53
순현금흐름:
$-12.27M
1주 성능:
-9.18%
1개월 성능:
+48.46%
6개월 성능:
-27.85%
1년 성능:
-3.50%
1일 변동 폭
Value
$3.85
$4.0797
1주일 범위
Value
$3.82
$4.42
52주 변동 폭
Value
$2.1501
$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name
명칭
Aprea Therapeutics Inc
Name
전화
617-463-9385
Name
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Name
직원
7
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
APRE's Discussions on Twitter

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-12-28 다운그레이드 Robert W. Baird Outperform → Neutral
2020-12-16 개시 Berenberg Buy
2020-09-29 재개 JP Morgan Neutral
2020-06-22 개시 H.C. Wainwright Neutral
2020-04-21 개시 Robert W. Baird Outperform
2019-10-28 개시 JP Morgan Neutral
2019-10-28 개시 Morgan Stanley Equal-Weight
2019-10-28 개시 RBC Capital Mkts Outperform
모두보기

Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스

pulisher
Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024
pulisher
Oct 29, 2024

Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR

Oct 28, 2024
pulisher
Oct 27, 2024

Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews

Oct 27, 2024
pulisher
Oct 26, 2024

Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 26, 2024

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Aprea therapeutics director sells shares worth $29,583 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News

Oct 23, 2024
pulisher
Oct 20, 2024

Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St

Oct 20, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

Director Bernd Seizinger Acquires 10,000 Shares of Aprea Therape - GuruFocus.com

Oct 15, 2024
pulisher
Oct 14, 2024

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - ForexTV.com

Oct 14, 2024
pulisher
Oct 11, 2024

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo

Oct 11, 2024
pulisher
Oct 10, 2024

Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Stonepine Capital Management, LLC Increases Stake in Aprea Thera - GuruFocus.com

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - ForexTV.com

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and - EIN News

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor - MyChesCo

Oct 10, 2024
pulisher
Oct 10, 2024

Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo

Oct 10, 2024
pulisher
Oct 09, 2024

APRE stock touches 52-week low at $2.22 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

APRE stock touches 52-week low at $2.22 amid market challenges - Investing.com UK

Oct 09, 2024
pulisher
Oct 09, 2024

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - The Manila Times

Oct 09, 2024
pulisher
Oct 08, 2024

Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

Halda appoints new chief executive - The Pharma Letter

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Acquires Shares of 137,174 Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Halda Therapeutics Appoints Christian Schade as CEO - citybiz

Oct 01, 2024

Aprea Therapeutics Inc (APRE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):